Skip to main content

Table 2 Performance of previously published protein prognostic biomarker candidates in OSskcm

From: OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles

Gene symbol

Literature data

Validation results

References

n

Survival endpoint

Prognostic significance of high expression

HR (95%CI)

Log-rank P value

Datasets

Cut off

KLK7

[20]

45

OS

Good

2.65 (1.27–5.53)†

0.0095

GSE17275

Upper 25%

     

3.60 (1.48–8.80)†

0.0049

GSE19234

Upper 25%

     

1.93 (1.40–2.65)†

< 0.0001

TCGA

Upper 25%

MITF

[29]

200

OS

Poor

1.43 (1.09–1.87)†

0.0104

TCGA

Upper 50%

     

3.46 (1.42–8.42)†

0.0063

GSE19234

Upper 50%

     

3.33 (1.18–9.41)†

0.0230

GSE98394

Upper 50%

KIF20A

[30]

61

RFS

Poor

2.17 (1.12–4.20)†

0.0218

GSE22155

Upper 25%

     

2.56 (1.20–5.47)†

0.0151

GSE50509

Upper 25%

     

3.21 (1.26–8.20)†

0.0147

GSE98394

Upper 25%

     

2.44 (1.02–5.83)†

0.0454

GSE19234

Upper 25%

CTHRC1

[31]

35

OS

Poor

3.41 (1.31–8.89)†

0.0122

GSE98394

Upper 25%

TFAP2A

[32]

Nearly 600

DSS

Poor

1.59 (1.03–2.47)‡

0.0379

GSE65904

Upper 25%

ATF2

[33]

544

OS

Poor

3.05 (1.56–5.97)†

0.0012

GSE22155

Upper 25%

NCOA3

[34]

343

RFS and DSS

Poor

1.79 (1.17–2.74)‡

0.0071

GSE65904

Upper 25%

BCL2

[35]

339

OS

Good

0.21 (0.04–0.97)†

0.0458

GSE22155

Upper 25%

BIRC5

[36]

50

DFS and OS

Poor

3.73 (1.44–9.67)†

0.0068

GSE98394

Upper 25%

MCAM

[37]

76

OS

Poor

4.66 (1.78–12.18)†

0.0017

GSE19234

Upper 25%

PLAT

[38]

214

DMFI and OS

Poor

2.24 (1.16–4.34)†

0.0164

GSE22155

Upper 25%

     

3.88 (1.47–10.24)†

0.0063

GSE98394

Upper 25%

NOS2

[39]

132

DSS and OS

Poor

1.41 (1.07–1.85)†

0.0131

TCGA

Upper 50%

CDKN1B

[40]

383

DSS and OS

Poor

0.48 (0.24–0.95)†

0.0341

GSE22155

Upper 25%

     

0.69 (0.50–0.95)†

0.0235

TCGA

Upper 25%

BCL6

[41]

88

6-year OS

Poor

0.57 (0.40–0.80)†

0.0011

TCGA

Upper 25%

FXYD5

[42]

115

OS

Poor

3.10 (1.24–7.76)†

0.0159

GSE19234

Upper 25%

DDIT3

[43]

106

OS

Good

5.74 (2.18–15.13)†

0.0004

GSE98394

Upper 25%

MCAT

[44]

1270

DFI and OS

Poor

5.75 (1.26–26.10)†

0.0236

GSE22155

Upper 25%

     

4.51 (1.72–11.82)†

0.0021

GSE98394

Upper 25%

CTNNB1

[45]

202

DSS

Good

1.55 (1.02–2.37)‡

0.0412

GSE65904

Upper 25%

     

1.75 (1.15–2.67)‡

0.0088

GSE65904

Upper 25%

AKT1

[46]

222

5-year DSS or OS

Poor

6.41 (2.39–17.23)†

0.0002

GSE98394

Upper 25%

     

1.53 (1.13–2.06)†

0.0056

TCGA

Upper 25%

RUNX3

[47]

421

5-year OS

Good

3.75 (1.36–10.33)†

0.0107

GSE50509

Upper 25%

   

5-year DSS

 

1.81 (1.18–2.76)‡

0.0062

GSE65904

Upper 25%

BBC3

[48]

158

5-year DSS or OS

Poor

3.62 (1.38–9.52)†

0.0092

GSE98394

Upper 25%

MMP2

[49]

157

DSS and RFS

Poor

1.41 (1.06–1.89)‡

0.0197

TCGA

Upper 50%

SPP1

[50]

345

RFS

Poor

9.42 (3.46–25.67)†

< 0.0001

GSE98394

Upper 25%

TNC

[51]

98

DFS

Poor

1.54 (1.01–2.34)‡

0.0434

GSE65904

Upper 25%

CCNA2

[52]

245

RFS

Poor

2.23 (1.02–4.88)†

0.0437

GSE50509

Upper 25%

RGS1

[53]

40

DSS

Poor

2.74 (1.03–7.24)†

0.0425

GSE98394

Upper 25%

     

3.24 (1.31–8.00)†

0.0110

GSE19234

Upper 25%

     

2.66 (1.07–6.65)†

0.0357

GSE19234

Upper 25%

SPARC

[54]

112

DFS

Poor

2.78 (1.21–6.34)†

0.0154

GSE50509

Upper 25%

CXCR4

[55]

71

DFS and OS

Poor

0.70 (0.51–0.97)†

0.0315

TCGA

Upper 25%

RBM3

[56]

246

OS

Good

NS

NS

–

–

EPAS1

[57]

46

DSS

Poor

3.51 (1.56–7.91)†

0.0024

GSE50509

Upper 25%

  1. NS not significance, RFS recurrence-free survival, DFS disease-specific survival, DFI disease-free interval, DMFI distant metastasis-free interval
  2. †,‡HR (95%CI) and Log-rank P value of overall survival (OS) and disease-specific survival (DSS)